Drugs / rhCG
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT03905603 | Oct 2019 → Apr 2026 | polycystic ovary syndrome | University of Virginia | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | rhCG | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03905603 ↗ |
| Route | Intravenous | “rhCG (Ovidrel) administered 250 mcg IV” NCT03905603 ↗ |